Adial Pharmaceuticals (ADIL)
(Delayed Data from NSDQ)
$0.46 USD
+0.02 (4.36%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $0.39 -0.07 (-14.30%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
Adial Pharmaceuticals, Inc.'s return on equity, or ROE, is -218.88% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.65%. While this shows that ADIL has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ADIL 0.46 +0.02(4.36%)
Will ADIL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADIL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADIL
Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know
ADIL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ADIL
Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's After-Market Session
Adial Pharmaceuticals (ADIL) Regains Nasdaq Compliance | ADIL Stock News